This page is intended for investors only
Proveca is the future Engine of Children’s Medicine
Proveca is a Paediatric-focused pharmaceutical company that prioritises improving children’s lives through the provision and licensing of the right paediatric medicines.
Proveca has established a unique set of skills and expertise required for developing medicines for children.
Proveca is leading the way for developing medicines specifically for children. Proveca understands that healthcare providers and parents need confidence regarding the safety, efficacy, right dosage form and palatability of a medicine for a child. Therefore Proveca ensures all of its medicines are designed with the child in mind.
What sets us apart
Only children’s medicines
Proveca is focused solely on the development and licensing of children’s medicines. The team draws on many years of paediatric experience in formulation, regulatory, medical and commercial.
Proveca’s expertise in this area is valued by healthcare providers as we work with them to understand the problems associated with providing the right management and medications specifically for children.
Making a difference
Proveca are developing more than just the formulations, we conduct clinical trials to demonstrate the efficacy and safety of our medicines, as well as demonstrating the effects on quality of life. We aim to register them as widely as possible to benefit children all over the world.
Proveca also look to make a difference by helping to educate healthcare providers and carers about the conditions of importance to them and how the child can be managed effectively. To this end, Proveca has been providing an educational series to healthcare professionals and is co-ordinating the development of relevant European guidelines, which will help to educate and inform those who treat and manage chronically sick children.
Identifying the child’s unmet need
Working with clinicians, pharmacists, nurses, parents, and patients, Proveca is able to understand the problems around medications, such as lack of dose suitability or administration difficulty. As a result, Proveca’s research and development department are continuously looking at suitable formulation alternatives. This can involve looking to provide age appropriate dose forms, which improve palatability and adherence in order to improve symptom control and quality of life for the child and their carers.
Reaching children around the world
Proveca have a global ambition in the paediatric medicines market, which is valued at £100 billion per annum in the US, Canada, Europe and Japan.
Proveca aim to be the leading Children’s Pharmaceutical company in the world by 2030, aiming to licence and distribute to many countries and continents, to ensure children have global access to the right medications.
Latest news
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
Published October 4 2024
Cessatech and Proveca announce world-wide (excluding US) commercial partnership for CT001
Proveca Expands Cardiology Portfolio through Licensing Agreement with Wockhardt UK
Published May 22 2024
Proveca is delighted to announce that on the 20th of March 2024, an agreement was reached with Wockhardt UK for the licensing and supply of a Captopril oral solution, marking a pivotal expansion in Proveca's cardiology portfolio.
The SALIVA trial publication
Published February 20 2024
On the 12th January the SALIVA study was published online in the Journal of Developmental Medicine and Child Neurology. The first and only double-blind, randomised, placebo controlled study for glycopyrronium bromide in sialorrhoea, that has investigated efficacy, tolerability and the effect on quality of life.